IL18 and myocardial infarction: In a C57BL/6 mouse model of myocardial infarction (MI) involving left anterior descending artery (LAD) occlusion, 14 days of postoperative delivery of MCC950 improved ejection fraction (26.7%), reduced myocardial fibrosis (13%), and reduced myocardial NLRP3, IL-1β, IL-18, and caspase-1 whilst decreasing immune cell infiltration [91].